Target- |
Mechanism- |
|
|
|
|
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Part A: Phase IB, Single Site, Dose-Escalation of SCD-101 and Part B: Randomized, Double-Blind, Placebo-Controlled Crossover of SCD-101 in Adults With Homozygous Sickle Cell Disease or S/Beta 0 Thalassemia.
The purpose of this study is to determine the safety and clinical effects of SCD-101 when given to adults with sickle cell disease.
100 Clinical Results associated with Invenux, Inc.
0 Patents (Medical) associated with Invenux, Inc.
100 Deals associated with Invenux, Inc.
100 Translational Medicine associated with Invenux, Inc.